Einer, C. ; Munk, D.E.* ; Park, E.* ; Akdogan, B. ; Nagel, J.* ; Lichtmannegger, J. ; Eberhagen, C. ; Rieder, T.* ; Vendelbo, M.H.* ; Michalke, B. ; Wimmer, R.* ; Blutke, A. ; Feuchtinger, A. ; Dershwitz, P.* ; DiSpirito, A.M.* ; Islam, T.* ; Castro, R.E.* ; Min, B.K.* ; Kim, T.W.* ; Choi, S.* ; Kim, D.* ; Jung, C.* ; Lee, H.* ; Park, D.* ; Im, W.* ; Eun, S.Y.* ; Cho, Y.H.* ; Semrau, J.D.* ; Rodrigues, C.M.P.* ; Hohenester, S.* ; Damgaard Sandahl, T.* ; DiSpirito, A.A.* ; Zischka, H.
ARBM101 (Methanobactin SB2) drains excess liver copper via biliary excretion in Wilson's disease rats.
Gastroenterology 165, 187-200.e7 (2023)
Background & Aims: Excess copper causes hepatocyte death in hereditary Wilson's disease (WD). Current WD treatments by copper-binding chelators may gradually reduce copper overload; they fail, however, to bring hepatic copper close to normal physiological levels. Consequently, lifelong daily dose regimens are required to hinder disease progression. This may result in severe issues due to nonadherence or unwanted adverse drug reactions and also due to drug switching and ultimate treatment failures. This study comparatively tested bacteria-derived copper binding agents—methanobactins (MBs)—for efficient liver copper depletion in WD rats as well as their safety and effect duration. Methods: Copper chelators were tested in vitro and in vivo in WD rats. Metabolic cage housing allowed the accurate assessment of animal copper balances and long-term experiments related to the determination of minimal treatment phases. Results: We found that copper-binding ARBM101 (previously known as MB-SB2) depletes WD rat liver copper dose dependently via fecal excretion down to normal physiological levels within 8 days, superseding the need for continuous treatment. Consequently, we developed a new treatment consisting of repetitive cycles, each of ∼1 week of ARBM101 applications, followed by months of in-between treatment pauses to ensure a healthy long-term survival in WD rats. Conclusions: ARBM101 safely and efficiently depletes excess liver copper from WD rats, thus allowing for short treatment periods as well as prolonged in-between rest periods.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Copper Depletion ; Liver ; Methanobactin ; Mitochondria ; Wilson's Disease; Cell-penetrating Peptides; Strain; Mechanisms; Binding; Penicillamine; Atpase; Atp7b
Keywords plus
Language
english
Publication Year
2023
Prepublished in Year
0
HGF-reported in Year
2023
ISSN (print) / ISBN
0016-5085
e-ISSN
1528-0012
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 165,
Issue: 1,
Pages: 187-200.e7
Article Number: ,
Supplement: ,
Series
Publisher
Elsevier
Publishing Place
1600 John F Kennedy Boulevard, Ste 1800, Philadelphia, Pa 19103-2899 Usa
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30203 - Molecular Targets and Therapies
30202 - Environmental Health
30205 - Bioengineering and Digital Health
Research field(s)
Enabling and Novel Technologies
Environmental Sciences
PSP Element(s)
G-505200-003
G-504800-002
G-500390-001
Grants
ArborMed Co. Ltd.
European Union
r Bildung und Forschung (BMBF)
Bundesministerium fuuml
Deutsche Forschungsgemeinschaft (DFG)
Copyright
Erfassungsdatum
2023-12-08